$Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy$

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

Axicabtagene ciloleucel (axi‐cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real‐world effectiveness of axi‐cel with efficacy and ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2024-05, Vol.99 (5), p.880-889
Hauptverfasser:	Lunning, Matthew A., Wang, Hai‐lin, Hu, Zhen‐Huan, Locke, Frederick L., Siddiqi, Tanya, Jacobson, Caron A., Ahmed, Sairah, Miklos, David B., Lin, Yi, Hill, Brian T., Ghobadi, Armin, Neelapu, Sattva S., Westin, Jason, Dieyi, Chrisopher, Field, Polly, Miao, Harry, Shahani, Shilpa A., Patel, Anik, Spooner, Clare, Fu, Christine, Muramoto, David, Xu, Hairong, Pasquini, Marcelo C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antigens, CD19 B-cell lymphoma Biological Products - therapeutic use Bone marrow transplantation Clinical trials Humans Immunotherapy, Adoptive Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Pathologic Complete Response Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!